AGENUS INC

Agenus Inc. (Nasdaq: AGEN) is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The company maintains its primary website at www.agenusbio.com.

The company's core business centers on immuno-oncology, where Agenus advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the patient population that may benefit from immunotherapy. The lead clinical program is botensilimab, a multifunctional anti-CTLA-4 antibody, which is being evaluated alone and in combination with balstilimab, a fully human monoclonal anti-PD-1 antibody. These investigational therapies have been evaluated in approximately 1,200 patients across more than 60 centers worldwide and across nine tumor types, including colorectal cancer, sarcoma, non-small cell lung cancer, hepatocellular cancer, pancreatic cancer, melanoma, ovarian cancer, and triple negative breast cancer. The company also maintains select clinical-stage immuno-oncology assets targeting multiple pathways including CD137, CD73, TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT.

Beyond its core immuno-oncology focus, Agenus maintains an equity investment in MiNK Therapeutics, Inc., valued at approximately 24.3 million dollars as of December 31, 2025, and holds majority ownership of SaponiQx, Inc., a subsidiary focused on saponin-based vaccine adjuvant discovery and manufacturing. The company also retains intellectual property and royalty interests in partnered programs through collaborations with major pharmaceutical companies including Bristol Myers Squibb, Incyte, and Merck & Co.

As of February 28, 2026, Agenus employed 81 people, including 19 with Ph.D. degrees and 5 with M.D. degrees. The company uses internal discovery, translational, clinical, and regulatory capabilities together with selected collaborations to advance its product candidates. Following a strategic realignment announced in December 2024, the company prioritized the botensilimab and balstilimab program while temporarily pausing certain non-core preclinical and clinical activities. In January 2026, Agenus closed a strategic collaboration with Zydus Lifesciences that included the sale of its biologics manufacturing facilities in Emeryville and Berkeley, California for total consideration of 91.0 million dollars.